Sr. Scientist

Analytical Development for Raw Materials

Posted on 5/20/2024



201-500 employees

Develops broad-spectrum bacterial infection vaccines



San Carlos, CA, USA

Required Skills
Data Analysis
  • PhD in Analytical Chemistry, Biochemistry or a related field with 3+ years of industry experience; MS or BS with 8+ years of industry experience in Pharma/Biotech
  • Extensive hands-on experience in a wide range of analytical techniques, such as UV-Vis, HPLC, CE, SDS-PAGE, icIEF, LCMS, GCMS, enzyme kinetics, colorimetric and fluorescent plate-based assays, ELISA, Western Blot, etc.
  • Familiar with regulatory standards and quality systems (e.g., GLP, GMP)
  • Ability to work in a fast-paced team environment, and to consistently meet aggressive timelines while prioritizing tasks for multiple projects
  • Must communicate complex scientific concepts clearly and precisely to a variety of audiences, including junior scientists, cross-functional teams, and non-scientific stakeholders
  • Effective communication and interpersonal skills, with the ability to collaborate cross-functionally and work effectively in a team environment
  • This position is a lab-based role and requires onsite presence
  • Independently perform method development across a broad range of analytical methods for raw materials for QC and characterization purpose to support pre-clinical and clinical projects
  • Oversee method transfer to external contract testing labs; Design and perform studies to assist troubleshooting of QC testing, method qualification/validation or issues related to the methods as needed
  • Perform analytical testing, data analysis and interpretation and present in various project and functional team meetings
  • Collaborate with cross-functional teams to achieve project timelines and goals
  • Maintain thorough and accurate records of laboratory work
  • Author analytical documents including but not limited to test method, protocols, and reports

Vaxcyte is centered on creating advanced vaccines such as VAX-24, a sophisticated 24-valent pneumococcal conjugate vaccine, by utilizing cutting-edge chemistry and the XpressCF™ cell-free protein synthesis platform. The company prioritizes developing high-fidelity, broad-spectrum vaccines to combat bacterial infections, continuously expanding its product pipeline with innovations like VAX-31 for various bacterial threats.

Company Stage


Total Funding



San Carlos, California



Growth & Insights

6 month growth


1 year growth


2 year growth